MIND MEDICINE MINDMED INC (MNMD)

Bullish Two Hundred Day Moving Average Cross - MNMD

MindMed to Be Added to the Nasdaq Biotechnology Index

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Mind Medicine Mindmed Breaks Below 200-Day Moving Average - Notable for MNMD

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

MindMed Announces New Employee Inducement Grants

Is Your Mind Ready to Consider Investing in Psychedelics Stocks?

Don't jump in without doing some research first.

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Notable Friday Option Activity: MNMD, TTD, SOC

MindMed to Participate in Upcoming Investor Conferences

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Notable Thursday Option Activity: PLNT, MNMD, GS

Bullish Two Hundred Day Moving Average Cross - MNMD

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

MindMed Announces New Employee Inducement Grants

MindMed to Participate in September Investor Conferences

Mind Medicine Mindmed (MNMD) Shares Cross Below 200 DMA

MNMD Stock Earnings: Mind Medicine Misses EPS for Q2 2024

MNMD stock results show that Mind Medicine missed analyst estimates for earnings per share the second quarter of 2024.

MNMD Stock Earnings: Mind Medicine Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Mind Medicine (NASDAQ:MNMD) just reported results for the second quarter of 202...

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference

MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update

Commit To Buy Mind Medicine Mindmed At $6, Earn 26.7% Annualized Using Options

MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

3 Psychedelic Stocks to Ride to the Moon and Beyond

Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market.